ArticleClinical and translational gastroenterology2026
Oxyntic Gland Intraepithelial T Lymphocytes as Progression Marker of Potential Autoimmune Gastritis.
Article in Clinical and translational gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Evolution of Autoimmune Gastritis Research (1995-2025): A Hybrid Bibliometric-Conceptual Synthesis.The Korean journal of helicobacter and upper gastrointestinal research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
introductionAutoimmune gastritis (AIG) is a chronic immune-mediated disease with potential for serious clinical consequences, yet early identification remains challenging. We aimed to assess whether deep oxyntic gland intraepithelial CD3 + T lymphocytosis may serve as a predictive histological marker of progression from potential -i.e., parietal cell antibody-positive patients without baseline gastric atrophy- to overt AIG.
methodsWe prospectively enrolled 45 adult parietal cell antibody-positive patients without histological evidence of mucosal atrophy between 2020 and 2022. All underwent upper gastrointestinal endoscopy with biopsies, and deep CD3 + intraepithelial lymphocytes (IELs) were quantified by immunohistochemistry. Patients were followed clinically and endoscopically for a median of 25 months. The primary end point was progression to overt AIG, defined histologically. Receiving operator curve analysis determined the optimal IEL cutoff for predicting progression. Gastrin-17 levels were assessed at baseline and follow-up.
resultsThirteen of 45 patients (28.9%) progressed to overt AIG. Progressors had significantly higher baseline deep CD3 + IEL counts (median 12.2 vs 3.9 per 100 epithelial cells, P < 0.01). A threshold of >7.1 IELs/100 cells yielded 92.3% sensitivity and 87.5% specificity (area under curve = 0.97). Baseline gastrin-17 levels did not differ significantly, but follow-up levels were markedly elevated in progressors (median 248 vs 37.4 pg/mL, P < 0.01). Patients who have not yet progressed are being followed up. DISCUSSION: Deep intraepithelial CD3 + lymphocytosis in the oxyntic mucosa is a strong predictor of AIG progression in patients with potential AIG. According to our preliminary results, IEL quantification should be considered in routine histological assessment to guide early risk stratification and follow-up strategies in potential AIG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.